FibroGen, Inc. (FGEN)
NASDAQ: FGEN · Real-Time Price · USD
0.313
+0.003 (0.93%)
Nov 7, 2024, 11:29 AM EST - Market open
FibroGen Employees
FibroGen had 486 employees as of December 31, 2023. The number of employees decreased by 106 or -17.91% compared to the previous year.
Employees
486
Change (1Y)
-106
Growth (1Y)
-17.91%
Revenue / Employee
$357,646
Profits / Employee
-$346,346
Market Cap
31.46M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Nortech Systems | 775 |
| Concord Medical Services Holdings | 727 |
| Neuronetics | 203 |
| AN2 Therapeutics | 41 |
| Daré Bioscience | 26 |
| Lipocine | 17 |
| Reviva Pharmaceuticals Holdings | 15 |
| Marker Therapeutics | 8 |
FGEN News
- 2 days ago - FibroGen to Report Third Quarter 2024 Financial Results - GlobeNewsWire
- 3 months ago - FibroGen, Inc. (FGEN) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - One Year, Five Trial Failures: FibroGen Terminates Pancreatic Cancer Treatment Program - Benzinga
- 3 months ago - FibroGen to Report Second Quarter 2024 Financial Results - GlobeNewsWire
- 5 months ago - FibroGen: Two New In-Licensed Oncology Drugs To Carry It Forward - Seeking Alpha
- 5 months ago - FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen's Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials - GlobeNewsWire
- 5 months ago - FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors - GlobeNewsWire
- 5 months ago - FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology - GlobeNewsWire